Christopher Fuglesang

CIK 1465835 · last filed 2021-04-01

Christopher Fuglesang is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for PAND, was dated Apr 1, 2021. Across all open-market trades the lifetime net is −$633.4M, making them a net seller over the disclosed history. 7 SEC filings were submitted jointly with Boxer Capital, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

-$633.40M

Filer Profile

Reported Address

11682 EL CAMINO REAL, SUITE 320
SAN DIEGO, CA 92130

Related Filers

Boxer Capital, LLC — 7 joint filings, latest 2024-01-25

Aaron I. Davis — 7 joint filings, latest 2024-01-25

Shehan Bharatha Dissanayake — 7 joint filings, latest 2024-01-25

JOSEPH LEWIS — 7 joint filings, latest 2024-01-25

MVA Investors, LLC — 7 joint filings, latest 2024-01-25

Boxer Asset Management Inc. — 6 joint filings, latest 2024-01-25

IVAN M LIEBERBURG — 4 joint filings, latest 2021-03-09

Braslyn Ltd. — 2 joint filings, latest 2024-01-25

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Pandion Therapeutics, Inc. (PAND) Delisted	Director	0	$60.05	$0	$13.00M	2	2021-04-01
Mirati Therapeutics, Inc. (MRTX) Delisted	10%+ Owner	1,765,560	$58.70	$103.64M	-$646.40M	1	2020-10-30

Recent Filings

3 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2021-04-01	Pandion Therapeutics, Inc. (PAND) Delisted	Mixed	−2,131,135	-$127.87M	EDGAR
2020-10-30	Mirati Therapeutics, Inc. (MRTX) Delisted	Mixed	—	-$646.40M	EDGAR
2020-07-21	Pandion Therapeutics, Inc. (PAND) Delisted	Mixed	+2,131,135	$13.00M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.